Michael D Macklin

US Patent:

7022320, Apr 4, 2006

Filed:

Feb 9, 2000

Appl. No.:

09/501328

Inventors:

Michael D. Macklin - Madison WI, US
Deborah L. Fuller - Madison WI, US

Assignee:

PowderJect Vaccines, Inc. - Wilmington DE

International Classification:

A61K 48/00
A61K 39/04
C07H 21/02
C07H 21/04

US Classification:

424 932, 4242481, 435 691, 435243, 4352531, 4353201, 435863, 514 44, 530350, 536 231, 536 237

Abstract:

Recombinant nucleic acid molecules are described. The molecules have a sequence or sequences encoding at least two antigens. Vectors and compositions containing these molecules are also described. In addition, compositions containing a cocktail of recombinant nucleic acid molecules having a sequence or sequences encoding one or more antigens are described. Methods of eliciting an immune response using these molecules and compositions are also described.

US Patent:

20020165176, Nov 7, 2002

Filed:

Apr 30, 2001

Appl. No.:

09/846091

Inventors:

Joel Haynes - Madison WI, US
Michael Macklin - Madison WI, US
Lendon Payne - Madison WI, US

International Classification:

A61K048/00

US Classification:

514/044000

Abstract:

Recombinant nucleic acid molecules are described. The molecules have a sequence or sequences encoding an influenza virus M2 antigen. Vectors and compositions containing these molecules are also described. Methods for eliciting an immune response using these molecules and compositions are also described.

US Patent:

56611323, Aug 26, 1997

Filed:

Nov 22, 1994

Appl. No.:

8/343401

Inventors:

Elof Eriksson - Welesley MA
Christophe Andree - Boston MA
William F. Swain - Madison WI
Michael D. Macklin - Middleton WI

Assignee:

Auragen, Inc. - Middleton WI

International Classification:

A61K 4800
C12N 1500

US Classification:

514 44

Abstract:

A DNA molecule encoding a secretable mature epidermal growth factor (EGF) polypeptide is delivered to a skin wound. The cells that take up the recombinant DNA construct express soluble EGF that is secreted into surrounding fluid. The presence of the EGF accelerates, by a statistically significant amount, the healing time of a wound treated in this manner. The DNA molecule can be a genetic construction that expresses an EGF encoding portion that differs from the naturally occurring EGF precursor gene in that the only coding region retained from the precursor gene is that of the mature EGF polypeptide. Amino-terminal EGF-like repeats and the carboxy-terminal hydrophobic sequence that anchors natural EGF to the cell membrane are not present in the genetic construction.